Total Fecal Microbiota Transplantation Alleviates High-fat Diet-induced Steatohepatitis in Mice Via Beneficial Regulation of Gut Microbiota
Affiliations
Non-alcoholic steatohepatitis (NASH) is an epidemic metabolic disease with limited therapeutic strategies. Cumulative data support the pivotal role of gut microbiota in NASH. Here, we investigated the hypothesis regarding whether fecal microbiota transplantation (FMT) is effective in attenuating high-fat diet (HFD)-induced steatohepatitis in mice. Mice were randomized into control, HFD and HFD + FMT groups. After an 8-week HFD, FMT treatment was initiated and carried out for 8 weeks. The gut microbiota structure, butyrate concentrations of the cecal content, liver pathology and intrahepatic lipid and cytokines were examined. Our results showed that after FMT, the gut microbiota disturbance was corrected in HFD-fed mice with elevated abundances of the beneficial bacteria Christensenellaceae and Lactobacillus. FMT also increased butyrate concentrations of the cecal content and the intestinal tight junction protein ZO-1, resulting in relief of endotoxima in HFD-fed mice. Steatohepatitis was alleviated after FMT, as indicated by a significant decrease in intrahepatic lipid accumulation (reduced Oli-red staining, decreased intrahepatic triglyceride and cholesterol), intrahepatic pro-inflammatory cytokines, and the NAS score. Accordingly, intrahepatic IFN-γ and IL-17 were decreased, but Foxp3, IL-4 and IL-22 were increased after FMT intervention. These data indicate that FMT attenuated HFD-induced steatohepatitis in mice via a beneficial effect on the gut microbiota.
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.
Devasia A, Ramasamy A, Leo C Int J Mol Sci. 2025; 26(4).
PMID: 40004240 PMC: 11855529. DOI: 10.3390/ijms26041778.
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD.
Geng W, Liao W, Cao X, Yang Y Biomedicines. 2025; 13(2).
PMID: 40002806 PMC: 11853636. DOI: 10.3390/biomedicines13020393.
Jiang X, Zheng Y, Sun H, Dang Y, Yin M, Xiao M CNS Neurosci Ther. 2025; 31(2):e70259.
PMID: 39957504 PMC: 11831070. DOI: 10.1111/cns.70259.
Monti E, Vianello C, Leoni I, Galvani G, Lippolis A, DAmico F Cells. 2025; 14(2).
PMID: 39851512 PMC: 11764391. DOI: 10.3390/cells14020084.
Wang L, Sun J, Chen S, Sun Y, Zheng Y, Feng J Front Med (Lausanne). 2025; 11():1490929.
PMID: 39839647 PMC: 11746088. DOI: 10.3389/fmed.2024.1490929.